Lakeside Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Lakeside Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-95,280	Closed	-$400K	–	62
2023 Q1	$400K	Hold	95,280	–	–	0.31%	43
2022 Q4	$573K	Hold	95,280	–	–	0.47%	34
2022 Q3	$555K	Sell	95,280 -2,500	-3%	-$15.6K	0.5%	32
2022 Q2	$584K	Hold	97,780	–	–	0.5%	32
2022 Q1	$457K	Hold	97,780	–	–	0.34%	36
2021 Q4	$242K	Buy	+97,780	New	+$239K	0.18%	49

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Lakeside Advisors's CTIC Position: Q2 2023 in Review

Lakeside Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 95,280 shares — an estimated $400K sold.

Lakeside Advisors first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $584K in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Lakeside Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Lakeside Advisors sold 95,280 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $400K.
Lakeside Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
Lakeside Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $584K in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Lakeside Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.